The EIC Pathfinder is one of the instruments of the 2023 European Innovation Council Work Programme, part of Horizon Europe. Do you have a high-risk/high-gain future technology that could result in a scientific breakthrough and make a real difference to our lives? Then the EIC Pathfinder Open may be suitable for your project.
The EIC Pathfinder programme aims to support early-stage projects (TRL levels 1 to 4) that have the potential to create new markets and address global changes. With a high-risk/high gain approach, a consortium of minimum 3 partners from academia or industry can work together to develop an innovative technology, based on science-towards-technology breakthrough research, up to the point of proof of principle. The results obtained from the research should lead to top publication, and, it is expected that following the Pathfinder, measures will be taken to ensure the continuation of the project, such as generating Intellectual Property.
Deadline: 7 March 2023 (expired)
Subsidy: max. €3M
Consortium: a consortium of minimum 3 partners from academia or industry (including SMEs) established in at least 3 different EU Member State countries can work together.
The EIC Pathfinder open call, is open to any type of technology and research area. Next to that, 5 EIC Pathfinder Challenges have been published for 2023, and have a top-down approach based on a specific topic. The EIC Pathfinder open call eligibility criteria and conditions also apply to the EIC Pathfinder Challenges, but, the information provided below is specific to the Challenges:
Deadline: 18 October 2023
Subsidy: max. €4M
Titles of the 5 EIC Pathfinder Challenges:
In our EIC Pathfinder 2023 Programme Guide we have gathered all available information for you on deadlines, budgets, consortia & more. A must read if you’re looking to gain access to our EIC experts’ advice and guidance for your EIC Pathfinder submission.
Catalyze is an official, trusted EIC Partner. All EIC supported projects and companies get access to coaching, mentoring, partnering and other EIC Business Acceleration Services.
Achilles Therapeutics (UK) is pushing the frontier of personalized adoptive T cell therapies. In the first round of the 2022 EIC Pathfinder program, an Achilles-led consortium was awarded €4 million from the “Emerging technologies in cell & gene therapy” Challenge, to develop a proof-of-concept, first-in-class, smart bioprocessing manufacturing platform.
A must-have if you’re interested in getting your business to the next level